Fundraising Fox
/Companies
Sign in

Diffusion Pharmaceuticals

NASDAQ: CRVO

Charlottesville, US · Founded 2015 · Delaware corporation · 1 known investors

Find your way into Diffusion Pharmaceuticals

Sign up to see every warm intro you have to Diffusion Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Diffusion Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CervoMed is a clinical-stage pharmaceutical/biotech company focused on developing drug treatments, progressing candidates from early- to late-stage development toward commercialization.

BiotechHealthtechMedical Devices

Founders & leadership

Diffusion Pharmaceuticals was founded in 2015 by John L. Gainer and David G. Kalergis.

JL
John L. GainerCo-founder
DGDavid G. Kalergis
David G. KalergisCo-founder
DR
David R. JonesExecutive
BL
Ben L. ShealyExecutive
JM
John MoynahanExecutive
SS
Stephen SimesExecutive
TB
Timothy BorisExecutive
YSYael Schwartz
Yael SchwartzExecutiveYael Schwartz is an Executive Officer and Director at CervoMed, a clinical-stage biopharmaceutical company developing neflamapimod for neurodegenerative diseases. She has expertise in clinical trials management and quality compliance.
CA
Craig AbolinExecutive
DS
David SherrisExecutive
JAJohn Alam
John AlamPresident and Chief Executive Officer, Director
DK
David K. KalergisNamed on SEC filing

Investors · 1

RA CapitalreportedBoston

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$134.5M disclosed across 9 rounds · 2014–2020

▶$750KraisedMay 2020 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert J. CobuzziDirector
  • Mark T. GilesDirector
  • David G. KalergisExecutive Officer, Director
  • Robert W. AdamsDirector
  • Thomas S. ByrneExecutive Officer
  • Alan G. LevinDirector
  • William K. HornungExecutive Officer
  • John L. GainerDirector
Offering amount
$750K
Amount sold
$750K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$625KraisedMay 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas S. ByrneExecutive Officer
  • Alan G. LevinDirector
  • Robert J. CobuzziDirector
  • William K. HornungExecutive Officer
  • John L. GainerDirector
  • Mark T. GilesDirector
  • Robert W. AdamsDirector
  • David G. KalergisExecutive Officer, Director
Offering amount
$625K
Amount sold
$625K
Sales commissions
$100K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$783.3KraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William K. HornungExecutive Officer
  • Thomas S. ByrneExecutive Officer
  • Mark T. GilesDirector
  • Alan G. LevinDirector
  • Robert W. AdamsDirector
  • David G. KalergisExecutive Officer, Director
  • John L. GainerExecutive Officer, Director
Offering amount
$783.3K
Amount sold
$783.3K
Sales commissions
$62.7K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$164.1KraisedJun 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas S. ByrneExecutive Officer
  • William K. HornungExecutive Officer
  • Alan G. LevinDirector
  • John L. GainerExecutive Officer, Director
  • Mark T. GilesDirector
  • David G. KalergisExecutive Officer, Director
  • Robert W. AdamsDirector
Offering amount
$164.1K
Amount sold
$164.1K
Sales commissions
$13.1K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.8MraisedMar 2017 · 145 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David G. KalergisExecutive Officer, Director
  • Thomas S. ByrneExecutive Officer
  • John L. GainerExecutive Officer, Director
  • Isaac BlechDirector
  • Alan G. LevinDirector
  • Robert W. AdamsDirector
  • Mark T. GilesDirector
  • Ben L. ShealyExecutive Officer
Offering amount
$25M
Amount sold
$15.8M
Sales commissions
$1.5M
Placement agents
Maxim Group LLC
First sale
Mar 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$85.7MraisedJan 2016 · 181 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David K. KalergisDirector
  • Mark T. GilesDirector
  • David R. JonesExecutive Officer
  • Thomas S. ByrneDirector
  • Robert W. AdamsDirector
  • Ben L. ShealyExecutive Officer
  • John L. GainerExecutive Officer, Director
  • Alan G. LevinDirector
Amount sold
$85.7M
Minimum investment
$1
First sale
Jan 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedDec 2015 · 28 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert W. AdamsDirector
  • David R. JonesExecutive Officer
  • Thomas E. ByrneDirector
  • Ben L. ShealyExecutive Officer
  • Alan LevinDirector
  • Mark T. GilesDirector
  • John L. GainerExecutive Officer, Director
  • David G. KalergisExecutive Officer, Director
Offering amount
$5M
Amount sold
$2.4M
Minimum investment
$5K
First sale
Dec 2015
Incorporated
Limited Liability Company, Virginia
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedSep 2014 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas E. ByrneDirector
  • Ben L. ShealyExecutive Officer
  • Robert W. AdamsDirector
  • David G. KalergisExecutive Officer, Director
  • Mark T. GilesDirector
  • John L. GainerExecutive Officer, Director
  • David R. JonesExecutive Officer
Offering amount
$3.5M
Amount sold
$3.5M
First sale
Jun 2014
Incorporated
Limited Liability Company, Virginia
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Diffusion Pharmaceuticals do?
CervoMed is a clinical-stage pharmaceutical/biotech company focused on developing drug treatments, progressing candidates from early- to late-stage development toward commercialization.
Who founded Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals was founded by John L. Gainer, David G. Kalergis in 2015.
Who are Diffusion Pharmaceuticals's investors?
Diffusion Pharmaceuticals's investors include RA Capital.
How much funding has Diffusion Pharmaceuticals raised?
Diffusion Pharmaceuticals has disclosed $134.5M raised across 9 rounds.
Where is Diffusion Pharmaceuticals headquartered?
Diffusion Pharmaceuticals is headquartered in Charlottesville, US.